Related Experiment Video
Updated: Jul 3, 2026

Patient-specific Modeling of the Heart: Estimation of Ventricular Fiber Orientations
Published on: January 8, 2013
The predictive role of the FIB-4 index in identifying arrhythmic risk among patients with nonischemic dilated
Firdevs Aysenur Ekizler1, Bahar Tekin Tak1, Serkan Cay1
1Department of Cardiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
Insights
The Fibrosis-4 (FIB-4) index can predict major arrhythmic events in patients with nonischemic dilated cardiomyopathy (NIDCM). This accessible marker helps identify high-risk individuals for closer monitoring and interventions.
Area of Science:
- Cardiology
- Biomarkers
- Arrhythmology
Background:
- Nonischemic dilated cardiomyopathy (NIDCM) poses challenges in identifying patients at risk for ventricular arrhythmias.
- The Fibrosis-4 (FIB-4) index, a liver fibrosis marker, shows potential in cardiovascular risk assessment.
- Current methods for risk stratification in NIDCM require further noninvasive tools.
Purpose of the Study:
- To investigate the association between FIB-4 index levels and the risk of major arrhythmic events in NIDCM patients.
- To determine if FIB-4 can serve as an independent predictor of adverse arrhythmic outcomes in this population.
Main Methods:
- A cohort of 1233 NIDCM patients was evaluated.
- The primary endpoint was a composite of sudden cardiac death, sustained ventricular tachycardia/fibrillation, or appropriate ICD therapy.
- Follow-up was conducted for a median of 70 months.
Main Results:
- The composite arrhythmic event occurred in 29.8% of patients during follow-up.
- A FIB-4 cut-off of 1.67 demonstrated 66% sensitivity and 81% specificity for predicting the primary endpoint.
- FIB-4 ≥ 1.67 was independently associated with increased arrhythmic risk (HR: 4.88, p < 0.001) after multivariate analysis.
Conclusions:
- The FIB-4 index is an independent predictor of major arrhythmic events and mortality in NIDCM patients.
- The readily available FIB-4 index can aid in identifying high-risk NIDCM patients.
- FIB-4 may guide closer monitoring or prophylactic interventions for at-risk individuals.
Background:
Identifying patients with nonischemic dilated cardiomyopathy (NIDCM) who are at increased risk for life-threatening ventricular arrhythmias remains a clinical challenge. The Fibrosis-4 (FIB-4) index, a noninvasive marker originally developed to evaluate liver fibrosis, has been shown to be associated with increased risk of adverse events in several cardiovascular diseases. This study aimed to investigate the relationship between FIB-4 levels and arrhythmic risk in patients diagnosed with NIDCM.
Methods:
A total of 1233 consecutive patients with NIDCM (714 men; 59.6 ± 12.4 years) were evaluated. The primary endpoint was the composite major arrhythmic event, including sudden cardiac death (SCD), documented sustained ventricular tachycardia or fibrillation, or appropriate implantable cardioverter defibrillator (ICD) therapy. Cardiovascular death and all-cause death were also evaluated as the secondary endpoints.
Results:
During a median follow-up period of 70 months (interquartile range: 60 to 85 months), the primary endpoint was developed in 367(29.8%) patients. ROC analysis showed that using a cut-off level of 1.67, FIB-4 predicted the occurrence of the composite primary endpoint with a sensitivity of 66% and specificity of 81%. On multivariate analysis, after adjusting for other confounding factors, FIB-4 ≥ 1.67 remained independently associated with arrhythmic risk (HR: 4.88, 95% CI: 3.92-6.07, p < 0.001).
Conclusions:
This study showed that the FIB-4 index is an independent predictor of major arrhythmic events and death in patients with NIDCM. As a readily available index, FIB-4 may offer additional value in identifying high-risk patients who may benefit from closer monitoring or prophylactic interventions in this patient population.
Related Concept Videos
Dysrhythmias V: Evaluating Dysrhythmias
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy III: Hypertrophic Cardiomyopathy